US Imposes Fresh Iran Oil Sanctions Despite Progress on Ceasefire Talks 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
New World Screwworm Found Near U.S. Border Raises Threat to Cattle Industry and Beef Prices 
Gold Prices Hold Near Record Levels as Inflation Concerns Offset Middle East Ceasefire Hopes 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Dollar Gains Slightly as U.S.-Iran Tensions Keep Forex Markets on Edge 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Oil Prices Jump After New U.S. Strikes on Iran Raise Supply Concerns 
US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
US Dollar Slips as Markets Weigh Potential US-Iran Peace Deal and Oil Price Outlook 
Gold Prices Slip as Stronger Dollar and Iran Peace Talk Uncertainty Weigh on Market 
US Quantum Stocks Surge After $2 Billion Government Investment 
NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
Celltrion biopharmaceutical company based in Incheon, South Korea, has become the largest shareholder in United Kingdom’s Iksuda Therapeutics biotech firm. This happened after the former acquired more stake in the antibody-drug conjugates (ADCs) developer’s company.
According to The Korea Herald, Celltrion now owns a 47.05% stake in Iksuda Therapeutics. It was able to buy more shares after securing a new growth fund. The South Korean leading drugmaker announced its latest acquisition on Wednesday, Jan. 25.
Celltrion shared it paid for the asset through direct investment and a fund it set up with Mirae Asset Capital. With the deal, Celltrion and the Mirae Asset Celltrion New Growth Fund are now the largest co-shareholders of Iksuda Therapeutics. The initial share that Celltrion owned prior to the new investment is unknown, as the company reportedly declined to say.
Moreover, the investment was made under the same contract terms that Celltrion and Mirae Asset Capital signed before. In the deal, they agreed to invest a total of KRW58 billion or about $47 million when they participated in the British biotech firm’s Series A financing round that took place in June 2021, as per The Korea Economic Daily.
With its increased share in Iksuda Therapeutics, Celltrion now expects to transform and expand its anti-cancer treatments by using the latter’s ADC technology for its biosimilar products - Herzuma and Truxima.
“We are working with and investing in various biotechnologies with promising platforms. We will be taking versatile measures to increase our influence in the growing ADC field,” the company said in a statement.
Iksuda Therapeutics mainly works on the development of the next-generation ADC for incurable cancer drugs. This is an anti-cancer tech that has been receiving a lot of attention recently because it was able to specifically attack cancer cells by simply connecting antibody drugs and chemical anti-cancer medicines.
